Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.

Danish drugmaker Novo Nordisk is launching its once-daily Wegovy pill in the United States on Monday, offering 1.5 milligram and 4 mg doses at $149 per month for self-paying patients in an intensely ...

Novo Nordisk's semaglutide, the active ingredient in Wegovy, mimics the action of the GLP-1 hormones, which play a role in regulating insulin and satiety. Wegovy is effective enough, but the company's ...

FRESNO, Calif. (KFSN) -- With weight-loss pills being released in the U.S. for the first time, the intensely competitive weight-loss market is becoming more affordable. Local experts are now weighing ...

Boehringer Ingelheim GmbH said patients using its experimental obesity shot lost 16.6% of their body weight in a large study, ...

Novo Nordisk is losing to Eli Lilly in the fiercely competitive weight loss market. But one of the company's mid-stage assets could help it remain a key player. Is there any hope left for the ...

So, when considering a company, one of the first things you'll want to look at is its competitive advantage, or moat. Like ...

The FDA approved oral semaglutide (Wegovy) for weight loss and reducing major adverse cardiovascular events. Novo Nordisk plans to launch the once-daily oral semaglutide in the US in early January ...

A new weight-loss drug that Eli Lilly is testing is helping patients in a late-stage trial lose an average of 28.7% of their body weight and offered "substantial" relief from osteoarthritis pain. In ...

Novo Nordisk's CagriSema could be a brand new growth driver for the company. Eli Lilly's orforglipron is breaking into a new, lucrative market. One of these companies should lead this market, but both ...